Noradrenaline Zentiva (Norepinephrine)

Norepinephrine stimulates alpha‑1 adrenergic receptors on blood vessels, causing vasoconstriction, and activates beta‑1 receptors in the heart, increasing contractility and heart rate. The combined effect raises systemic vascular resistance and cardiac output, improving blood pressure and tissue perfusion.

The dose of Noradrenaline Zentiva is individualized by the prescribing clinician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Dosing is typically titrated intravenously in a critical‑care setting.

Safety data for norepinephrine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under strict medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Norepinephrine is considered the first‑line vasopressor for most shock states because of its balanced alpha‑ and beta‑adrenergic activity. Compared with agents such as phenylephrine (pure alpha agonist) or dopamine (dose‑dependent effects), norepinephrine provides more predictable increases in blood pressure with fewer tachyarrhythmic events.

Noradrenaline Zentiva must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is supplied as an injectable solution for intravenous infusion. It is typically administered through a central venous catheter, with the infusion rate adjusted continuously based on the patient’s blood pressure and clinical response.

Serious risks include severe hypertension, myocardial infarction, tissue necrosis from extravasation, and cardiac arrhythmias. Continuous hemodynamic monitoring is essential to detect and manage these complications promptly.

Patients with known hypersensitivity to norepinephrine or any excipients in the formulation should not receive the product. Caution is also advised in individuals with uncontrolled hypertension, severe peripheral vascular disease, or those receiving MAO inhibitors.